73
Views
16
CrossRef citations to date
0
Altmetric
Original Research

Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence

, , , , , , , , , & show all
Pages 213-222 | Published online: 09 May 2011

Figures & data

Figure 1 Patient disposition.

Figure 1 Patient disposition.

Table 1 Antipsychotic switch patterns at study entry

Figure 2 Twelve-month Kaplan–Meier survival curve (n = 406) for all cause treatment discontinuation (event, n = 99; censored, n = 307). Time to discontinuation was calculated from the date of study entry to the date of the first all cause treatment discontinuation. For the survival analyses, patients were censored if they had not switched, augmented, or discontinued their antipsychotic medication at 365 days, if they had completed the study, or if they discontinued from the study for any reason. Censored patients are denoted by •. Median Kaplan–Meier estimates could not be calculated because the proportion of patients who had changed their medication during the study did not reach 50% at 12 months.

Figure 2 Twelve-month Kaplan–Meier survival curve (n = 406) for all cause treatment discontinuation (event, n = 99; censored, n = 307). Time to discontinuation was calculated from the date of study entry to the date of the first all cause treatment discontinuation. For the survival analyses, patients were censored if they had not switched, augmented, or discontinued their antipsychotic medication at 365 days, if they had completed the study, or if they discontinued from the study for any reason. Censored patients are denoted by •. Median Kaplan–Meier estimates could not be calculated because the proportion of patients who had changed their medication during the study did not reach 50% at 12 months.

Table 2 Reasons for all cause treatment discontinuation

Table 3 Antipsychotic medication use patterns for all cause treatment discontinuation

Table 4 Change in illness severity, attitude to antipsychotic medication, and quality of life scores